

Pioneering Personalisation in Pan Tumour: Tissue and Liquid Sequencing with AI Insights for Therapy Optimisation



Friday, 12 June 2026
13:15-14:15 (BST)



Harewood 2, Crowne Plaza
Harrogate Convention Centre
Harrogate, United Kingdom

Invitation to Caris Life Sciences Sponsored Symposium

This interactive symposium brings together leading oncology experts for an engaging session examining comprehensive molecular profiling (CMP) and the future of AI insights in precision oncology. Gain real-world insights from clinical practice to explore how CMP could improve patient outcomes by unlocking more actionable targets and more treatment options.

Symposium Agenda

- **Foundations of Precision Oncology:** Integration of comprehensive molecular profiling (WES/WTS) as standard of care for advanced cancer patients
- **Clinical Case Discussion:** NGS and biomarker insights for patient-centric therapy selection and treatment strategies
- **Next Generation Sequencing Frontier:** Clinical utility of AI insights for clinical practice and Molecular Tumour Boards (MTBs)

Learning Objectives

- Evaluate CMP data to inform personalised, patient-centric therapy selection, integrating biomarker insights, clinical guidelines, and toxicity considerations for patients with advanced or metastatic cancer.
- Develop an understanding of CMP strategies across diverse tumour types to optimise treatment selection beyond first-line therapy.
- Assess current and emerging evidence, including real-world data and case-based insights, to support the integration of CMP into standard-of-care practice.

The symposium is organised and funded by Caris Life Sciences and will contain discussion of Caris Life Sciences products. This activity is designed for oncologists, pathologists, and other healthcare professionals involved in the care of patients with cancer across all disease stages, aiming to improve therapy selection and treatment outcomes.



Professor Hendrik-Tobias Arkenau, PhD, FRCP

Consultant Medical Oncologist, Leaders in Oncology Care – HCA Healthcare UK
Chief Medical Officer and Global Head of Drug Development, Ellipses Pharma



Professor Andrew M. Wardley, FRCP, FACP (UK)

Professor, CEO of Cancer Services